SPL RF Jan 2021
EN_01459393_0320
![SPL RF Jan 2021](img/medium/arch35/dvd0424/67/EN_01459393_0320.jpg)
SPECIAL RATES FOR EDITORIAL AND BOOKS
RF RATES FOR OTHER USE - INTERNET +100%
Internet +100%
RNA vaccine, conceptual illustration. A molecule of RNA (ribonucleic acid, blue helix) is being injected at right. The RNA is taken up and read by the body's cells, causing them to produce copies of viral proteins (red). The viral proteins provoke an immune response, leading to the production of antibodies (purple) against the protein, and priming the body against infection with the actual virus. The first RNA vaccine approved for human use, developed against the SARS-CoV-2 coronavirus by Pfizer/BioNTech, was approved in the UK on 2nd December 2020.
2021-01-02
DESIGN CELLS/Science Photo Library RF/East News
Science Photo Library RF
DESIGN CELLS
f0325891
6,47MB
61cm x 34cm by 300dpi
1ST, ACID, ANTIBODIES, ANTIBODY, ANTIGEN, ARTWORK, BIOLOGICAL, BIOLOGY, BIONTECH, BIOTECHNOLOGICAL, BIOTECHNOLOGY, BODY, CELLS, CONCEPTS, CONCEPTUAL, CONDITION, CORONAVIRUS, COVID-19, DESIGN, DISEASE, DISORDER, EPIDEMIC, FIRST, HCOV, HUMAN, ILLUSTRATION, IMMUNE, IMMUNISATION, IMMUNISING, IMMUNITY, IMMUNIZING, IMMUNOGLOBULIN, MESSENGER, MRNA, NO-ONE, NOBODY, PANDEMIC, PFIZER, PROTEIN, RESPONSE, RIBONUCLEIC, RNA, SARS-COV, SARS-COV-2, SYSTSEM, VACCINATING, VACCINATION, VACCINE, VIRAL,